Acadia Pharmaceuticals Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare Conference
ACADIA Pharmaceuticals Inc. (ACAD)
Last acadia pharmaceuticals inc. earnings: 2/26 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.acadia-pharm.com/phoenix.zhtml?c=125180&p=irol-irhome
Company Research
Source: Business Wire
- 2028 projected combined net sales of approximately $1.7 billion including ~$1 billion for NUPLAZID® and ~$700 million for DAYBUE®- Top-line results from the Phase 2 RADIANT study of remlifanserin (formerly ACP-204) in Alzheimer’s disease psychosis anticipated between August and October 2026- U.S. launch of DAYBUE® STIX on a limited basis begins Q1 2026, with full launch planned Q2 2026 SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced multiple business updates and progress on the Company's neurological and rare disease drug candidates, which will be discussed today during a presentation by Catherine Owen Adams, Chief Executive Officer, at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA.“2026 marks a pivotal year for Acadia as we advance our strategy built for sustained growth and pipeline advancement,” said Catherine Owen Adams, Chief Executive Officer. “With approximately $1.7 billion in global projected net sales by 20
Show less
Read more
Impact Snapshot
Event Time:
ACAD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ACAD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ACAD alerts
High impacting ACADIA Pharmaceuticals Inc. news events
Weekly update
A roundup of the hottest topics
ACAD
News
- ACADIA Pharmaceuticals Targets $1.7B Sales by 2028, Maps Key Remlifansirin Readouts at JPM Conf [Yahoo! Finance]Yahoo! Finance
- Acadia Pharmaceuticals Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- ACADIA Pharmaceuticals (NASDAQ:ACAD) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=ACAD&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StMarketBeat
- ACADIA Pharmaceuticals (NASDAQ:ACAD) was given a new $40.00 price target on by analysts at UBS Group AG. They now have a "buy" rating on the stock.MarketBeat
- ACADIA Pharmaceuticals (NASDAQ:ACAD) had its "buy" rating reaffirmed by analysts at Citigroup Inc..MarketBeat
ACAD
Earnings
- 11/5/25 - Beat
ACAD
Sec Filings
- 1/13/26 - Form 8-K
- 11/19/25 - Form 4
- 11/19/25 - Form 4
- ACAD's page on the SEC website